c/o Lab Central
700 Main Street
2 articles with Cyteir Therapeutics
Biotech companies are dominating Nasdaq’s IPO scheduled this week. Here’s who is making their big public debut.
Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors
Novel, targeted, oral drug candidate inhibits DNA-repair protein to induce cell death in multiple cancer types including pancreatic cancer and B-cell non-Hodgkin lymphoma